KARACHI: Ferozsons Laboratories Limited (PSX: FEROZ) delivered a strong financial performance for the nine months ended March 31, 2026, reporting a significant increase in profitability driven by higher sales and improved operating performance.
According to the company’s latest financial results, net revenue climbed to Rs11.95 billion, up from Rs10.81 billion recorded during the same period last year. The increase in sales helped lift gross profit by more than 16% to Rs4.99 billion, compared with Rs4.29 billion a year earlier.
Profit after taxation rose to Rs503.87 million, marking an increase of around 29% from Rs390.44 million reported in the corresponding period of FY2025. As a result, earnings per share (EPS) improved to Rs11.59, compared with Rs8.98 in the same period last year.
The company’s operating profit also strengthened, reaching Rs1.07 billion versus Rs994.86 million a year earlier. Meanwhile, finance costs declined significantly to Rs223.66 million from Rs357.08 million, providing additional support to bottom-line growth despite higher administrative, selling, and distribution expenses.
For the third quarter alone, Ferozsons Laboratories posted Rs3.66 billion in revenue and earned a net profit of Rs150.25 million, translating into quarterly EPS of Rs3.46, compared with Rs3.18 in the corresponding quarter of the previous year.
The company’s balance sheet also reflected continued growth. Total assets increased to Rs16.59 billion as of March 31, 2026, from Rs15.68 billion at the end of June 2025. Shareholders’ equity improved to Rs9.70 billion, supported by higher accumulated profits of Rs6.35 billion.
On a consolidated basis, the group reported an even stronger performance. Consolidated revenue surged to Rs18.17 billion, while profit after taxation reached Rs919.68 million. Profit attributable to shareholders stood at Rs735.45 million, resulting in consolidated EPS of Rs16.92, compared with Rs13.12 in the same period last year.
The latest results underscore Ferozsons Laboratories’ continued growth momentum, supported by expanding revenues, stronger operational performance, and lower financing costs, positioning the pharmaceutical company for a solid finish to the fiscal year.
